Bringing Gene Therapies for HIV Disease to Resource-Limited Parts of the World

Overview

Journal Hum Gene Ther

Specialties Genetics
Pharmacology

Date 2020 Oct 1

PMID 32998595

Citations 5

Authors

Joseph M McCune

Emily H Turner

Adam Jiang

Brian P Doehle

Affiliations

Soon will be listed here.

Citing Articles

Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?.

Harper J, Betts M, Lichterfeld M, Muller-Trutwin M, Margolis D, Bar K Pathog Immun. 2024; 8(2):115-157.

PMID: 38455668 PMC: 10919397. DOI: 10.20411/pai.v8i2.665.

The promise of a "cure" for HIV: implications for the future of PEPFAR-supported HIV programmes.

Raizes E, Blandford J, McCune J, Dybul M J Int AIDS Soc. 2024; 27(1):e26206.

PMID: 38193636 PMC: 10775627. DOI: 10.1002/jia2.26206.

The long-term impact and value of curative therapy for HIV: a modelling analysis.

Guzauskas G, Hallett T J Int AIDS Soc. 2023; 26(9):e26170.

PMID: 37749063 PMC: 10519941. DOI: 10.1002/jia2.26170.

Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States.

Dube K, Kanazawa J, Patel H, Louella M, Sylla L, Sheehy J BMC Med Ethics. 2022; 23(1):39.

PMID: 35397551 PMC: 8994300. DOI: 10.1186/s12910-022-00780-1.

Collaborative science to advance gene therapies in resource-limited parts of the world.

McCune J, Stevenson S, Doehle B, Trenor 3rd C, Turner E, Spector J Mol Ther. 2021; 29(11):3101-3102.

PMID: 34464598 PMC: 8571166. DOI: 10.1016/j.ymthe.2021.05.024.

References

Cohen J, Kaiser J . Gates and NIH join forces on HIV and sickle cell diseases. Science. 2019; 366(6465):558-559. DOI: 10.1126/science.366.6465.558-b. View

Luzuriaga K, Gay H, Ziemniak C, Sanborn K, Somasundaran M, Rainwater-Lovett K . Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med. 2015; 372(8):786-8. PMC: 4440331. DOI: 10.1056/NEJMc1413931. View

Rajawat Y, Humbert O, Kiem H . In-Vivo Gene Therapy with Foamy Virus Vectors. Viruses. 2019; 11(12). PMC: 6950547. DOI: 10.3390/v11121091. View

Dash P, Kaminski R, Bella R, Su H, Mathews S, Ahooyi T . Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nat Commun. 2019; 10(1):2753. PMC: 6606613. DOI: 10.1038/s41467-019-10366-y. View

BERGER E, Murphy P, Farber J . Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999; 17:657-700. DOI: 10.1146/annurev.immunol.17.1.657. View

Noel N, Jacquelin B, Huot N, Goujard C, Lambotte O, Muller-Trutwin M . Interferon-associated therapies toward HIV control: The back and forth. Cytokine Growth Factor Rev. 2018; 40:99-112. DOI: 10.1016/j.cytogfr.2018.03.004. View

Embgenbroich M, Burgdorf S . Current Concepts of Antigen Cross-Presentation. Front Immunol. 2018; 9:1643. PMC: 6054923. DOI: 10.3389/fimmu.2018.01643. View

Taieb F, Tran Hong T, Thi Ho H, Nguyen Thanh B, Pham Phuong T, Ta D . First field evaluation of the optimized CE marked Abbott protocol for HIV RNA testing on dried blood spot in a routine clinical setting in Vietnam. PLoS One. 2018; 13(2):e0191920. PMC: 5806875. DOI: 10.1371/journal.pone.0191920. View

Bertagnolli L, White J, Simonetti F, Beg S, Lai J, Tomescu C . The role of CD32 during HIV-1 infection. Nature. 2018; 561(7723):E17-E19. PMC: 6442722. DOI: 10.1038/s41586-018-0494-3. View

10.

Wykes M, Lewin S . Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2017; 18(2):91-104. PMC: 5991909. DOI: 10.1038/nri.2017.112. View

11.

Cisneros G, Thein S . Recent Advances in the Treatment of Sickle Cell Disease. Front Physiol. 2020; 11:435. PMC: 7252227. DOI: 10.3389/fphys.2020.00435. View

12.

Henrich T, Hatano H, Bacon O, Hogan L, Rutishauser R, Hill A . HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med. 2017; 14(11):e1002417. PMC: 5675377. DOI: 10.1371/journal.pmed.1002417. View

13.

Casado C, Galvez C, Pernas M, Tarancon-Diez L, Rodriguez C, Sanchez-Merino V . Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. Sci Rep. 2020; 10(1):1902. PMC: 7002478. DOI: 10.1038/s41598-020-58696-y. View

14.

Broeders M, Herrero-Hernandez P, Ernst M, van der Ploeg A, Pijnappel W . Sharpening the Molecular Scissors: Advances in Gene-Editing Technology. iScience. 2020; 23(1):100789. PMC: 6941877. DOI: 10.1016/j.isci.2019.100789. View

15.

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8. DOI: 10.1056/NEJMoa0802905. View

16.

Galvani A, Novembre J . The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect. 2005; 7(2):302-9. DOI: 10.1016/j.micinf.2004.12.006. View

17.

Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak A, Nell R, Tomescu C . CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med. 2018; 10(437). PMC: 6282755. DOI: 10.1126/scitranslmed.aar6759. View

18.

Descours B, Petitjean G, Lopez-Zaragoza J, Bruel T, Raffel R, Psomas C . CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature. 2017; 543(7646):564-567. DOI: 10.1038/nature21710. View

19.

Rodger A, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O . Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019; 393(10189):2428-2438. PMC: 6584382. DOI: 10.1016/S0140-6736(19)30418-0. View

20.

Collins D, Gaiha G, Walker B . CD8 T cells in HIV control, cure and prevention. Nat Rev Immunol. 2020; 20(8):471-482. PMC: 7222980. DOI: 10.1038/s41577-020-0274-9. View